NURO NeuroMetrix Inc.

NeuroMetrix Named a 50+ Innovation Leader

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it was selected as one of the healthcare industry’s 50+ Innovation Leaders under an AARP initiative administered by MedCity News to recognize entrepreneurs, companies, and ideas behind innovative new products and services for Americans aged 50 and older.

The winners of the inaugural 50+ Innovation Leaders program were revealed today during the AARP Innovation@50+ LivePitch event by representatives of MedCity News and AARP.

NeuroMetrix is applying neurotechnology to address the chronic pain epidemic with a 100% drug free, wearable technology solution called Quell®. The FDA cleared device works by stimulating the sensory nerves in the upper calf, which carry neural pulses to the brain, activating the body’s natural pain blockers. Quell was designed to meet the needs of people with conditions like arthritis, back pain, leg pain, and nerve pain, who are looking for better options to manage their pain without side effects.

“Quell empowers those living with chronic pain to reclaim their life through advanced technology. Being recognized as a 50+ Innovation Leader confirms that we are serving the chronic pain community well, and will continue to provide innovative, alternative options for treatment,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “We are always striving to provide solutions for the over 100 million Americans feeling the effects of chronic pain.”

“AARP works to empower people to choose how they live as they age,” said Jeffrey Makowka, AARP’s Director of Market Innovation. “We are pleased to join MedCity News in showcasing entrepreneurs who are driving change and improvements in the healthcare industry for the more than 100 million Americans aged 50 and older. We congratulate the remarkable winners who have been recognized by their peers for their innovation leadership.”

In late 2016, MedCity News and AARP issued a call for nominations for entrepreneurs, investors, companies, and nonprofit collaborations. Determined by a reader vote, the winners include leaders and companies offering healthcare delivery, medication management, and smart wearables.

The full list of winners can be seen at medcitynews.com/50-plus-innovation-leaders/.

About AARP

AARP is the nation’s largest nonprofit, nonpartisan organization dedicated to empowering Americans 50 and older to choose how they live as they age. With nearly 38 million members, and offices in every state, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and advocate for what matters most to families with a focus on health security, financial stability and personal fulfillment. AARP also works for individuals in the marketplace by sparking new solutions and allowing carefully chosen, high-quality products and services to carry the AARP name. As a trusted source for news and information, AARP produces the world’s largest circulation publications, AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org or follow @AARP and @AARPadvocates on social media.

About MedCity News

MedCityNews is the leading online news source for the business of innovation in healthcare. We offer insight into what’s next and what matters with a mix of breaking news and analysis on startups and established industry leaders, personalities, policies and the most important deals. Learn more at www.medcitynews.com or follow @medcitynews on social media.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

EN
13/04/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuroMetrix Inc.

Neurometrix Inc: 1 director

A director at Neurometrix Inc sold 20,000 shares at 13.560USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable T...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle. "We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is co...

 PRESS RELEASE

NeuroMetrix Closes $3.5 Million Equity Offering

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company’s common stock closed on October 30, 2017 at $1.80 per share. Proceeds of the offering will be used for commercialization of Quell®, the Company's over-the-counter wearable device for relief of chronic pain and for general work...

 PRESS RELEASE

NeuroMetrix Reports Q3 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that pro...

 PRESS RELEASE

NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Resu...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 84863406. Internationally, the co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch